Viking Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In San Diegocaliforniathe Company Focuses On Developing Innovative Therapies For Metabolic And Endocrine Disordersemploying A Team Of 46 Professionals Dedicated To Advancing Its Investigational Treatments Viking S Pipeline Includes Several Key Products Targeting Various Conditionsvk2809 Is An Oral Thyroid Hormone Receptor Beta Agonist In Phase Iib Trials For Non Alcoholic Steatohepatitisnashand Liver Fibrosisvk2735 Is A Dual Agonist For Glp 1 And Gip Receptorsaimed At Addressing Obesity And Diabetesvk0214 Is An Oral Therapy For X Linked Adrenoleukodystrophyx Ald A Rare Neurological Disorderwhile Vk0612 Is Being Investigated For Type 2 Diabetesthe Company Emphasizes Tissue Selective Receptor Targeting To Reduce Off Target Effectswith A Focus On Orally Administered Therapiesviking Therapeutics Is Committed To Advancing Its Clinical Programswhich Primarily Target Patients With Nashx Aldand Metabolic Syndromethe Company Is Actively Working To Bring Its Candidates Through Clinical Trialsreflecting Strong Investor Interest In Its Pipeline
No conferences found for this company.
| Company Name | Viking Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
